These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Depo-provera: clinical evaluation.
    Author: Mukherjea M.
    Journal: Contracept Deliv Syst; 1981 Jul; 2(3):259-69. PubMed ID: 12278913.
    Abstract:
    A collaborative contraceptive study was conducted for over 2 years in order to assess the acceptability of Depo-Provera to women in the Calcutta region of India. 138 women were enrolled in the study for a total of 907 women-months. The median age was 25 years. 77.7% had only 1 or 2 children and 3.4% had 5 or more. Each women received a 150 mg dosage intramuscularly of Depo-Provera. Subsequent injections were given at 90 day intervals. Maximum duration of the study was 24 months. 32% discontinued after the first injection while 38.8% of the women discontinued during the first 6 months. Among the 237 menstrual cycles followed up 3 months after the first injection 89 cycles (37.5%) showed amenorrhea, 87 cycles (36.7%) showed bleeding and/or spotting lasting 1-7 days per 30 day period, and 42 cycles (17.7%) showed bleeding and/or spotting for more than 15 days per 30 day cycle. A larger percentage of women became amenorrheic (62% after 1 year, 57% after 2 years) with long term treatment. The percentage of women with excessive bleeding remained at 16-17% for 1 year and gradually decreased to 2.8%. Body weight increased significantly from 9 months of treatment onward. Analysis of endometrial biopsies after treatment with Depo-Provera for more than 1 year showed that most (87.5%) were of the atrophic type. The clinical effects of Depo-Provera contraception did not indicate any major adverse reaction and the minor side effects were similar in type but less than those recorded for various oral contraceptives. The success rate of Depo-Provera as a contraceptive agent on a 90 day regimen was 99.3%. It is the conclusion of the study that this dosage of Depo-Provera appears to be accepted and tolerated by parous women in the Calcutta region.
    [Abstract] [Full Text] [Related] [New Search]